Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 270 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MWrGeY5kfGmxbjDBd5NigQ>? MlvYNE44|ryP M2G3bFI1cA>? NVfH[oIy\XSqYX7vcC=> NF;YWFVmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn MX[yOVc5PzB5OR?=
TE13 NGGxZnlHfW6ldHnvckBCe3OjeR?= NUDwbpA6OC5|zszN M37SR|I1cA>? Moj5eZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= MX2yOVU4QTZ4NR?=
TE13 NULiS3B5SXCxcITvd4l{KEG|c3H5 MXSwMlPPxE1? Mn;NNlRp MVXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MmTaNlU2Pzl4NkW=
MEFs MWnGeY5kfGmxbjDBd5NigQ>? Ml\GOe69VQ>? M2fKVlE3cA>? M2Hlbolv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? MXGyOVQ5OjZ|NB?=
SW480  NXLD[nBLTnWwY4Tpc44hSXO|YYm= M2jNPFAvOc7:TR?= M4rUb|Q5cA>? NIXVWZVFVVOR NILY[XRz\X[ncoPld{BGVVR? M{DmdlI2PDN2OUm3
PC3  NXq3VopVTnWwY4Tpc44hSXO|YYm= M4TyUFAvOc7:TR?= NHrV[Wg1QGh? MV3EUXNQ M{DiRpJmfmW{c3XzJGVOXA>? NWDDeXpnOjV2M{S5PVc>
SW480  M4e0SGZ2dmO2aX;uJGF{e2G7 NEOzWFMxNjIQvF2= NYDhUoxXPDiq M4rjeWROW09? NWrnPFZ2[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u M3[0XlI2PDN2OUm3
PC3  NYTLTJpUTnWwY4Tpc44hSXO|YYm= MVKwMlHPxE1? MYS0PIg> NXLnVFBXTE2VTx?= MnTHZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M1HxelI2PDN2OUm3
SW480  M{\xR2Z2dmO2aX;uJGF{e2G7 NIf5TXUxNjIQvF2= NW[xbIp4PDiq NUjFemhKTE2VTx?= M1H5N4lv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MWGyOVQ{PDl7Nx?=
PC3  MVHGeY5kfGmxbjDBd5NigQ>? MlnNNE4y|ryP MoXYOFhp Mmr4SG1UVw>? NXvnNWNCcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= M2TY[|I2PDN2OUm3
A431 MkTXRZBweHSxc3nzJGF{e2G7 M2fzclIwOTBxNUCvNVAxdk1? NVrwWGVuPDiq NIPlb4pFVVOR Mn7ybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq NVzHSXVmOjV|N{GwOlk>
A431 NFjRblRHfW6ldHnvckBCe3OjeR?= NXrT[4N5PTCwTR?= M1mwN|IwPi9zMj:yOIg> NHrTVFlFVVOR NIWwdo5i[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= NFXlTokzPTN5MUC2PS=>
MDA-MB-231 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17xWVAuPjBybl2= MWWyOIg> NInuTWJFVVOR NGq5fIFKSzVyIH;mJFExOG6P MlS4NlUyQTJ5MkG=
MCF7 NF3iWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHONE03ODCwTR?= MmrHNlRp MlS0SG1UVw>? M2\WcGlEPTBib3[gO|VvVQ>? MknsNlUyQTJ5MkG=
SKOV-3 M3jxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDtNU0yOM7:TR?= NVXlVHNuOjSq MoO4SG1UVw>? M1HvTmlEPTBib3[gOU43|ryP NEOxOW0zPTF4OUS5NS=>
A549 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu1TolKOS1zMN88US=> MlqyNlRp M2nIfmROW09? Moj6TWM2OCCxZjCzMlLPxE1? MV[yOVE3QTR7MR?=
SKOV-3 NYXJe3dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPLWJAxNjFvMd88US=> NIT4Nos1QGh? M2\JOWROW09? NEDJbGhKSzVyIH;mJFAvP87:TR?= M{DDOVI2OTZ7NEmx
A549 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PJTlAvOS1zzszN NWK5WZZzPDiq NEmx[FJFVVOR NIn0NY1KSzVyIH;mJFAvOjkQvF2= MYCyOVE3QTR7MR?=
SKOV-3 NIDtZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ONE4xOS1yLkpOwG0> MYi3Nog> Ml\SSG1UVw>? M{G1ZWlEPTBib3[gNE4{Os7:TR?= MmLxNlUyPjl2OUG=
A549 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTxU5J1OC5yMT2wMlnPxE1? NF\6W5g4Omh? MYXEUXNQ NYDWe2lyUUN3MDDv[kAxNjB4zszN MmDwNlUyPjl2OUG=
HeLa NVu0OYpLTnWwY4Tpc44hSXO|YYm= MnnDNlUxdk1? NYjiSphNOT[q MoDVSG1UVw>? M3mxUIlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= M{jZbFI2OTF4Nki4
CNE2 NVLwcnB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYTWcyODBvNkCwcm0> NYjvfWxwOjRxNEivO|Jp M{LIVYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVfiU5FwOjR7Nkm5NFE>
PC3 NX32Xo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\hNVAxNTFyMEDuUS=> MUCyOIg> NVzmcWhtUUN3MDDv[kA{ODCwTR?= MYWyOFg2PDZ3OB?=
LNCaP NIXRb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TtcFExOC1zMECwcm0> NFmycVgzPGh? NHzuN5BKSzVyIH;mJFMxOG6P NHHtflgzPDh3NE[1PC=>
HeLa  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmy{txO Mnu1OFhp MoPh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= MV[yOFg1PjF|NR?=
HMEC-1  NEDITo5HfW6ldHnvckBCe3OjeR?= NX7Lbm1YOzBybl2= M1fHd|I1cA>? MYXpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MYKyOFcyODZ|MR?=
HeLa MWDGeY5kfGmxbjDBd5NigQ>? M1zyfVFuVQ>? MWOwMlVp NUPNUGNr[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 NUS5e2tnOjR5MEe0O|Q>
ACP02 M4K0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm4T25IOjVyL{O1NE82ODCwTR?= NFLrd3ozPGh? NGjoWWtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P M2HxbVI1PjZ6NUS3
ACP03 M2jLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7EfGh3OjVyL{O1NE82ODCwTR?= MmPONlRp Ml[x[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NIHzNm0zPDZ4OEW0Oy=>
U87 GBM MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTUNVAxNzNyMD:1NFAhdk1? M1[3TlczKGh? MVmxNFAmKGW2aHHuc4w> MYry[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= NFz3d2UzPDR4NEi0NS=>
U87 GBM NHrJfm9HfW6ldHnvckBCe3OjeR?= M1nSWlExOC93MECgUo0> M2LRT|Q5KGh? NXXoVlBqOTByJTDleIhidm:u MlXrTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 NHTTVW8zPDR4NEi0NS=>
RPE MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMlIwOC52L{CuPE8yKM7:TR?= Ml\iNlQwPDhxN{KgbC=> NGr3RZdFVVOR NWTZVJV[cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? M3fjSlI1PDV4NkCy
HT29  NGXiWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq1NVgxKG6P NWnnUGxYPzJiaB?= MmDlTWM2OCCxZjCxPFAhdk1? MYCyOFM3QDJ4NR?=
hMSCs Mnr6SpVv[3Srb36gRZN{[Xl? NYrpXlkzPi5{NTDuUS=> NV3hZ5FmOjRiaB?= Mm\GSG1UVw>? NV7VRYJye3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> M2jNbFI1OzF{M{W2
Huh7  M33Vc2Z2dmO2aX;uJGF{e2G7 MViwMlEwOC53L{GuNEDPxE1? MUiyOIg> Ml\4d5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w MkPRNlQzPjl4N{K=
SKOV3 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG5Z44xNjB3LUKg{txO NWW1UIJoOTBxMkSvOFghcA>? MXTEUXNQ NUjKd3V3dWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnfTNlQzOjN6MEG=
A2780 NYL5OFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq5NE4xPS1{IN88US=> MV6xNE8zPC92ODDo MW\EUXNQ NWnSRlMydWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MVWyOFIzOzhyMR?=
SRA01/04  MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH24e4wxNjJizszN MljLOFghcA>? MY\EUXNQ M4HieJN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NXTwcW9MOjRzNUe4O|g>
HLEB3 NG[wSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmOYMxNjJizszN NY\CN5Y5PDhiaB?= NHriRWxFVVOR Ml3Id5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> MXqyOFE2Pzh5OB?=
SRA01/04  NFr0TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LYcFAvPC9yLkig{txO NVXjPWg6PDhiaB?= M3LGTGROW09? M1[yPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MoW1NlQyPTd6N{i=
HLEB3 NU[0RWdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnVVAvPC9yLkig{txO M1;LRVQ5KGh? NYXpOIZHTE2VTx?= M1\NfYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUiyOFE2Pzh5OB?=
HCT116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfOcFUxNjJizszN NVrocGZ4OTJiaB?= MVflcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= Ml\UNlQyOjJ{M{G=
CA46 NHXBW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y0cFMwPi9zMj:yOE81QCCwTR?= NVjKNHRzPDhiaB?= MnLDbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? MWOyOFA3PDl3MR?=
PMNs NHnO[otHfW6ldHnvckBCe3OjeR?= NXjZe5dROzBibl2= MnnJOFghcA>? MlnnbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 M3PsTFI{QTh6NkG3
H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H4dVHDqM7:TdMg NHzpdo0zPC92OD:3NkBp MVPleIhidm:u M4D1N4lv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? MVqyN|kyPjZyOR?=
A549 M1nkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCNE4zPS9yLkWvNUDPxE1? MVSyOE81QC95MjDo M2P2XoV1cGGwb3y= M2TSc4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MYWyN|g3Pzl7MR?=
H1299 NFmwSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ISWc2OC5{NT:wMlUwOSEQvF2= MWWyOE81QC95MjDo M{XmfYV1cGGwb3y= NWr3cpVVcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnzpNlM5Pjd7OUG=
A549 NUT4e|lESXCxcITvd4l{KEG|c3H5 MVqwMlUwOSEQvF2= NFXG[Gc1QCCq M4DLO4V1cGGwb3y= M1LoRolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NV;tcZVlOjN6Nke5PVE>
H1299 NYiyVGtPSXCxcITvd4l{KEG|c3H5 MXWwMlUwOSEQvF2= Mn\IOFghcA>? M4Xk[YV1cGGwb3y= Mn3NbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MmK2NlM5Pjd7OUG=
SUM149PT Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH0d|l7Oi95LkWvNVAh|ryP NVjNXZR{PDhiaB?= Mn\1SG1UVw>? NWC5SVdVcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= NXe5SJpoOjN5OUK2N|g>
SUM190PT Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PFWlUxNzFyMD:yOVAhdk1? MVS0PEBp M1:1UmROW09? NEPSbGdqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MlHjNlM4QTJ4M{i=
HCT1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmwMlIwOS5yL{WuNEDPxE1? M4fmZlEzNzJ2L{O2M|Q5KGh? NVrSRnJocW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M{fKSlI{PzdyMECw
Lovo M3zld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3UNE4zNzFwMD:1MlAh|ryP NELSSmoyOi9{ND:zOk81QCCq NX6xXI0xcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M4G0c|I{PzdyMECw
AGS NFvZS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqwMlAyPS1zIN88US=> NFr0SVY4OiCq M2GzR4lv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M4[0TFI{PzR3MEK0
Huh7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;6[ZZ6OSEQvF2= NGTkVJIzPCCq NWLXT2NiTE2VTx?= NHfxclFz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? M2C5NFI{PjR|OUOz
ECC1 NHnueW5HfW6ldHnvckBCe3OjeR?= Mm\wOVAxKG6P NGH6Z4w2KGR? M3Tt[2ROW09? NVXnSI97cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= M3PhNlI{PTNyN{[5
HEC1A MWfGeY5kfGmxbjDBd5NigQ>? M4TyXlUxOCCwTR?= NXvlTpNlPSCm NWjjVFk4TE2VTx?= MYXpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MoSzNlM2OzB5Nkm=
EN1 M13WemZ2dmO2aX;uJGF{e2G7 NUXUfVVUPTByIH7N M{HZTlUh\A>? MnPQSG1UVw>? NI\abGRqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MnLNNlM2OzB5Nkm=
MFE296 MmT2SpVv[3Srb36gRZN{[Xl? M1GyT|UxOCCwTR?= MUG1JIQ> MVvEUXNQ NF7zZYJqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M4nlS|I{PTNyN{[5
HASMCs MXXGeY5kfGmxbjDBd5NigQ>? NH6yV24xNTVyMDDuUS=> MXm2JIQ> NVrPOlh1\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? Mm\yNlM2OTh2Nke=
U373 NYq5d4N[TnWwY4Tpc44hSXO|YYm= M1nwfFAvOjVxMD61M|Eh|ryP MV:yOEBp MlzNbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? M4PNfFI{PDd2MUex
ARN8  NFPYfHNHfW6ldHnvckBCe3OjeR?= M1fB[VAvODVvMjFOwG0> NUHwUVEyOjRiaB?= MYPy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> M3L3cFI{PDdyNUSw
MCF7 M3HC[mZ2dmO2aX;uJGF{e2G7 NHPuZ|IxNjB3LUKg{txO M3LteVI1KGh? MkTUdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NGrv[nQzOzR5MEW0NC=>
H1299  NIj0cGJHfW6ldHnvckBCe3OjeR?= MknNNE4{O+LCk{JCpOK2VQ>? Mn7uNlQwPDhiaB?= NXP1UY1yTE2VTx?= NEOyeHFqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 MYGyN|Q3OTl5NR?=
H1299 NU\tSZdMTnWwY4Tpc44hSXO|YYm= NVXafolrOC53IN88US=> MXO0PEBp M3fOXGROW09? Mny0bY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> MVWyN|Q3OTl5NR?=
H1299 MmCxSpVv[3Srb36gRZN{[Xl? NX\3UWZ6OC53IN88US=> MWC0PEBp M2XjRWROW09? MlTJbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? NXT4[GpPOjN2NkG5O|U>
MG-63  MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf3cJhHOC5|IN88US=> NF3wWFMyOi17NjDo NWHQR2JWTE2VTx?= M3zJOYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= NXfGbIFUOjN2NUG4NVc>
LM8 M{HrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrzU5A2OC5|IN88US=> NXGxWGFvOTJvOU[gbC=> MUPEUXNQ NVr3bmIzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MUKyN|Q2OThzNx?=
K562 MkLsSpVv[3Srb36gRZN{[Xl? MXuwMlUh|ryP MlvwNlQhcA>? M4PNboV1cGGwb3y= NIPkbWNl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NFz1cYkzOzR|MEm1Oy=>
HEL NWja[Y1yTnWwY4Tpc44hSXO|YYm= NYLFOnJlOC53IN88US=> NHzUZ4czPCCq MXjleIhidm:u NYPt[3Vs\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NVjpWlR1OjN2M{C5OVc>
HL60 MmXhRZBweHSxc3nzJGF{e2G7 NUCzOG1MOSEQvF2= NHXaZlIzPCCq MUnpcoR2[2W|wrDj[YxtKGSnYYTo NFrqcoozOzRyMEWxPS=>
KG1 MUjBdI9xfG:|aYOgRZN{[Xl? NIPUc4oyKM7:TR?= MWSyOEBp NEX6WYdqdmS3Y3XzxsBk\WyuIHTlZZRp NIDxSoQzOzRyMEWxPS=>
Kazumi NFzlbG1CeG:ydH;zbZMhSXO|YYm= M1rPTlEh|ryP MXSyOEBp NIT5OIZqdmS3Y3XzxsBk\WyuIHTlZZRp NEL6WYwzOzRyMEWxPS=>
K562 MnrpRZBweHSxc3nzJGF{e2G7 NGDLRWkyKM7:TR?= NYCydJBFOjRiaB?= MnO5bY5lfWOnc9MgZ4VtdCCmZXH0bC=> NV:1XXZZOjN2MEC1NVk>
THP1 NY\Id|NXSXCxcITvd4l{KEG|c3H5 Ml7jNUDPxE1? NHPudJkzPCCq NGPW[G9qdmS3Y3XzxsBk\WyuIHTlZZRp NYn4NlBvOjN2MEC1NVk>
SH-SY5Y NYHocWllTnWwY4Tpc44hSXO|YYm= Mlz2NlUxKG6P MXSxOkBp MmKzZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= NVjsdHgyOjN|Mk[0NlI>
HEK293 NICwW|VHfW6ldHnvckBCe3OjeR?= Mnj6NUDDvU4EoB?= MlzaNVghcMLi MoSwbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? M17De|I{Ojh2OES4
HTK MkDPSpVv[3Srb36gRZN{[Xl? MX:0NFAhdk1? NIfCb2Y4OiCq Ml2xbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> M37pdVI{Ojh2MECy
HTK NGHkNldHfW6ldHnvckBCe3OjeR?= MlvwNVAxNThyMH7N Mn;hO|IhcA>? M3nOTYJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NVPxbIRpOjN{OESwNFI>
Caco-2  NHzac49HfW6ldHnvckBCe3OjeR?= M2ixUVEhyrWPwrC= NUTWOWpQOjRiaB?= NWfoeFR[\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u MmPJNlMyQTVyN{C=
HeLa MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rY[VExOCCwTR?= Mn3ONlQhcA>? M2DBemROW09? MXnJR|UxKG:oIEGwNI5O M3;3dlI{OTZ3N{S4
HeLa NFH0WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\Uc|QxKG6P NHPSVo41QCCq MV7EUXNQ M2LQV2lEPTBib3[gOFBvVQ>? NW\MdWs3OjNzNkW3OFg>
HeLa MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37jSFIxKG6P MVO3NkBp MUTEUXNQ M4KxTGlEPTBib3[gNlBvVQ>? Mn;1NlMyPjV5NEi=
HeLa MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\1N|ExNzNyL{WwJI5O NWG0OYZGPzJiaB?= MVzEUXNQ Mn3QbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 M{HoSFI{OTZ3N{S4
MDA-MB-231 NInoU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyyOU01ODBibl2= MYS0PEBp MX3JR|UxKG:oIEK2N{4zdk4EoB?= M{K1NVI{ODV3MUm4
MCF-7  M2XsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5cFczPS12MECgcm0> NWjrcolrPDhiaB?= MWHJR|UxKG:oIEKyNE41dk1? NGriSIszOzB3NUG5PC=>
ECC-1  NI\jUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTiNVAxKG6P NVXVUZJrOjRiaB?= NWfBcWE{\XSqYX7vcC=> M3jrOIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= NXfadnN1OjNyMki4NFM>
HEC-1A NHfpfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZNVAxKG6P MUmyOEBp MYTleIhidm:u MoWxbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln NFjNPHozOzB{OEiwNy=>
NHAC-kn MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n0O|ExNzFyMD:1NFAhdk1? MUOxNkBp MX3EUXNQ NXTwfYFoUUN3MDDv[kA2ODCwTR?= MlPNNlMxOTd6N{G=
A549 NIXPbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfENlUxKG6P M13mW|YuPzJiaB?= NIDqcG9FVVOR MlOzZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> M4\TTlIzQTl2N{iw
MG-63 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jmOlMxOCCwTR?= MV6xNkBp M3iw[WROW09? M1\U[IlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? M{PVbVIzPzl7M{O4
MG-63 M4X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXUN|AxKG6P M3jZWVI1KGh? NGrJPJRFVVOR NHzT[oVqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NVnCUpdsOjJ5OUmzN|g>
MG-63 NFP4doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXN|AxKG6P NI[2Tmo1QCCq MV;EUXNQ MkfhbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? M2rRPVIzPzl7M{O4
HL60  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fqXFE2OC1|NUCgcm0> MYSyOEBp NXrBZo5rcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NH76Ro8zOjd3M{ezPS=>
U937 NGXNdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDod3gyPTBvM{WwJI5O NVO3eINDOjRiaB?= M{i1eYlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> NXn5WYs2OjJ5NUO3N|k>
SCC-6 NXXkOlJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWyNFAuOzJyMDDuUS=> NX7wbY1TOTJxMkSvOFghcA>? MXfEUXNQ NYjQOoJocW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NWXMbIN6OjJ3NUKzNlE>
U87  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXjeWJDOTByLUOwNEBv\w>? NFHhT3MzPCCq NVzHVVRzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= NH\jS4MzOjJ5MEi0PS=>
K562 MWHGeY5kfGmxbjDBd5NigQ>? NV\CTYd4OSEQvF2= M2DzVlEzKGh? MWDEUXNQ M3nvR4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS Ml6zNlIyPzlzOUi=
Reh NEC2VVhHfW6ldHnvckBCe3OjeR?= MnrUNE4{NzFizszN M1X1[|EzKGh? M3zMNmROW09? NWO1e5pP\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MoGyNlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID